AU2014296255B2 - 1,4-disubstituted pyridazine derivatives and their use for treating SMN-deficiency-related conditions - Google Patents

1,4-disubstituted pyridazine derivatives and their use for treating SMN-deficiency-related conditions Download PDF

Info

Publication number
AU2014296255B2
AU2014296255B2 AU2014296255A AU2014296255A AU2014296255B2 AU 2014296255 B2 AU2014296255 B2 AU 2014296255B2 AU 2014296255 A AU2014296255 A AU 2014296255A AU 2014296255 A AU2014296255 A AU 2014296255A AU 2014296255 B2 AU2014296255 B2 AU 2014296255B2
Authority
AU
Australia
Prior art keywords
methyl
pyridazin
amino
tetramethylpiperidin
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014296255A
Other languages
English (en)
Other versions
AU2014296255A1 (en
Inventor
Atwood Cheung
Natalie Dales
Timothy Brian Hurley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2014296255A1 publication Critical patent/AU2014296255A1/en
Application granted granted Critical
Publication of AU2014296255B2 publication Critical patent/AU2014296255B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014296255A 2013-07-31 2014-07-30 1,4-disubstituted pyridazine derivatives and their use for treating SMN-deficiency-related conditions Ceased AU2014296255B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860388P 2013-07-31 2013-07-31
US61/860,388 2013-07-31
PCT/US2014/048984 WO2015017589A1 (en) 2013-07-31 2014-07-30 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions

Publications (2)

Publication Number Publication Date
AU2014296255A1 AU2014296255A1 (en) 2016-02-18
AU2014296255B2 true AU2014296255B2 (en) 2017-08-03

Family

ID=51352849

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014296255A Ceased AU2014296255B2 (en) 2013-07-31 2014-07-30 1,4-disubstituted pyridazine derivatives and their use for treating SMN-deficiency-related conditions

Country Status (14)

Country Link
US (3) US20160184305A1 (enExample)
EP (2) EP4105208A1 (enExample)
JP (3) JP6461150B2 (enExample)
KR (2) KR102318727B1 (enExample)
CN (1) CN105636953B (enExample)
AU (1) AU2014296255B2 (enExample)
BR (1) BR112016001899B1 (enExample)
CA (1) CA2918805C (enExample)
EA (1) EA030631B1 (enExample)
ES (1) ES2917979T3 (enExample)
MX (2) MX383686B (enExample)
PL (1) PL3027600T3 (enExample)
PT (1) PT3027600T (enExample)
WO (1) WO2015017589A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
MX383686B (es) * 2013-07-31 2025-03-14 Novartis Ag Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
JP6884102B2 (ja) * 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための化合物
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
CN107635999B (zh) * 2015-05-20 2020-09-25 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的化合物
US10357543B2 (en) 2015-11-16 2019-07-23 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein
KR102488323B1 (ko) 2015-12-10 2023-01-12 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
KR20200033249A (ko) 2017-06-05 2020-03-27 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
JP2020523365A (ja) 2017-06-14 2020-08-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを改変する方法
WO2019000150A1 (zh) * 2017-06-26 2019-01-03 深圳市博奥康生物科技有限公司 一种tl6高表达的重组cho细胞的构建方法
WO2019000144A1 (zh) * 2017-06-26 2019-01-03 深圳市博奥康生物科技有限公司 一种表达aitr基因的cho细胞及其应用
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111194215B (zh) 2017-08-04 2024-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
AU2019294478B2 (en) 2018-06-27 2023-03-23 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603595B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
WO2021014428A1 (en) 2019-07-25 2021-01-28 Novartis Ag Regulatable expression systems
MX2022005254A (es) 2019-11-01 2022-06-29 Novartis Ag El uso de un modulador de empalme para un tratamiento que retrasa la progresion de la enfermedad de huntington.
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
EP4119151A4 (en) 2021-06-03 2023-10-25 MD Healthcare Inc. Composition for preventing or treating eye diseases comprising extracellular vesicles derived from lactobacillus paracasei

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1466547A (en) * 1974-06-10 1977-03-09 Thomae Gmbh Dr K 5-6-pyridazin-6-yl-benzimidazole derivatives
WO2007137030A2 (en) * 2006-05-19 2007-11-29 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
WO2009150139A2 (en) * 2008-06-10 2009-12-17 Neurosearch A/S Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods
WO2011036167A1 (en) * 2009-09-22 2011-03-31 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2012127393A1 (en) * 2011-03-18 2012-09-27 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
WO2014028459A1 (en) * 2012-08-13 2014-02-20 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2427943C2 (de) * 1974-06-10 1984-08-02 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
BR9408137A (pt) 1993-11-24 1997-08-12 Du Pont Merck Pharma Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição
HUP0301391A3 (en) * 2000-02-11 2010-03-29 Vertex Pharma Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use
EP1133993A1 (en) * 2000-03-10 2001-09-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Substances for the treatment of spinal muscular atrophy
EP1289993B9 (en) * 2000-06-07 2008-08-20 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6376508B1 (en) * 2000-12-13 2002-04-23 Academia Sinica Treatments for spinal muscular atrophy
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
PL375256A1 (en) 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
US20040132726A1 (en) 2002-08-09 2004-07-08 Astrazeneca Ab And Nps Pharmaceuticals, Inc. New compounds
ATE345342T1 (de) 2002-11-11 2006-12-15 Neurosearch As 1,4-dizabicyclo(3,2,2)nonane derivative, verfahren zur ihre herstellung und therapeutical verwendung
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
EP1642898B1 (en) 2003-06-27 2013-03-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
US7666862B2 (en) 2003-08-15 2010-02-23 Merck & Co., Inc. Mitotic Kinesin Inhibitors
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7655657B2 (en) * 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
FR2868780B1 (fr) 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
EP1753740A2 (en) 2004-05-21 2007-02-21 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
AU2005283085B2 (en) 2004-06-18 2012-06-21 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
PL1637141T3 (pl) 2004-09-21 2012-04-30 Trobio Ab Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej
MX2007004551A (es) 2004-10-18 2007-05-23 Amgen Inc Compuestos tiadiazol y metodos de uso.
DE602006008945D1 (de) 2005-06-28 2009-10-15 Sanofi Aventis Isochinolinderivate als inhibitoren von rho-kinase
EP2233470B1 (en) 2005-07-04 2011-12-07 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
GB0517184D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
TW200813051A (en) * 2006-05-08 2008-03-16 Neurogen Corp Substituted azaspiro derivatives
WO2008005368A2 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008058064A1 (en) 2006-11-07 2008-05-15 Lexicon Pharmaceuticals, Inc. Amine-linked multicyclic compounds as inhibitors of the proline transporter
CA2673003A1 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
GB0704394D0 (en) 2007-03-07 2007-04-11 Senexis Ltd Compounds
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EA019509B1 (ru) 2007-11-16 2014-04-30 Райджел Фармасьютикалз, Инк. Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений
ES2647531T3 (es) * 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Derivados de heteroarilo como moduladores de CFTR
WO2009137503A1 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Hdac inhibitors and uses thereof
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
CA2735593C (en) * 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
EP2350039A4 (en) 2008-10-03 2012-10-10 Boehringer Ingelheim Int INHIBITORS OF VIRAL POLYMERASE
WO2010045306A2 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
JP5785089B2 (ja) 2008-11-04 2015-09-24 ケモセントリックス，インコーポレイティド Ｃｘｃｒ７の調節因子
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
CN102573842A (zh) * 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
WO2011029804A1 (en) 2009-09-10 2011-03-17 F. Hoffmann-La Roche Ag Inhibitors of jak
CN102740698A (zh) * 2009-11-18 2012-10-17 普莱希科公司 用于激酶调节的化合物和方法及其适应症
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011130515A1 (en) 2010-04-14 2011-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2012022467A2 (en) * 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
MX383686B (es) 2013-07-31 2025-03-14 Novartis Ag Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1466547A (en) * 1974-06-10 1977-03-09 Thomae Gmbh Dr K 5-6-pyridazin-6-yl-benzimidazole derivatives
WO2007137030A2 (en) * 2006-05-19 2007-11-29 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
WO2009150139A2 (en) * 2008-06-10 2009-12-17 Neurosearch A/S Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods
WO2011036167A1 (en) * 2009-09-22 2011-03-31 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2012127393A1 (en) * 2011-03-18 2012-09-27 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
WO2014028459A1 (en) * 2012-08-13 2014-02-20 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUNNELLE, W.H. et al, Journal of Medicinal Chemistry, 2009, vol. 52, pp. 4126-4141 *
LI, J. et al, Journal of Neuroimmunology, 2011, vol. 239, pp. 37-43 *
LI, T. et al, Bioorganic & Medicinal Chemistry Letters, 2010, vol. 20, pp. 3636-3639 *

Also Published As

Publication number Publication date
MX383686B (es) 2025-03-14
CN105636953B (zh) 2018-01-02
US11672799B2 (en) 2023-06-13
KR20160037199A (ko) 2016-04-05
EP4105208A1 (en) 2022-12-21
KR102318727B1 (ko) 2021-10-28
BR112016001899A2 (enExample) 2017-09-05
JP6461150B2 (ja) 2019-01-30
KR20210130843A (ko) 2021-11-01
PL3027600T3 (pl) 2022-08-08
PT3027600T (pt) 2022-06-23
BR112016001899B1 (pt) 2022-03-15
EA030631B1 (ru) 2018-09-28
CN105636953A (zh) 2016-06-01
MX2020011652A (es) 2022-09-27
US20160184305A1 (en) 2016-06-30
CA2918805A1 (en) 2015-02-05
EP3027600A1 (en) 2016-06-08
US20240009189A1 (en) 2024-01-11
JP2021098753A (ja) 2021-07-01
MX2016001400A (es) 2016-05-05
JP6856614B2 (ja) 2021-04-07
CA2918805C (en) 2023-02-28
EA201690287A1 (ru) 2016-07-29
US20190160062A1 (en) 2019-05-30
ES2917979T3 (es) 2022-07-12
JP2019059783A (ja) 2019-04-18
JP7208285B2 (ja) 2023-01-18
EP3027600B1 (en) 2022-04-06
WO2015017589A1 (en) 2015-02-05
AU2014296255A1 (en) 2016-02-18
JP2016527272A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
US11672799B2 (en) 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions
US9040712B2 (en) Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
JP6190883B2 (ja) １，４−二置換ピリダジン類似体およびｓｍｎ欠損に関連する状態を処置するための方法
AU2013302859B9 (en) 1,4-disubstituted pyridazine analogs and methods for treating SMN-deficiency-related conditions
HK40012123A (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired